SIGN-UP NOW! SIGN-UP NOW! Click to become a VoiceAmerica Member for Free!
Voiceamerica radio logo
voiceamerica-health-and-wellness radio logo
Apple logo Google Play Store Kindle store
C. diff. Spores and More
top banner

C. diff. Spores and More

Tuesday at 10 AM Pacific

March 31st 2015:Synthetic Biologics Preventing C diff Infection with SYN-004

The majority of C. difficile cases are caused by the unintended consequences of antibiotic therapy to the gut microbiome. Intravenous (IV) antibiotics excreted to the gut often wipe out the natural balance of microflora, which can lead to recurring diarrhea and perforation of the intestinal wall, with potentially fatal outcomes. Co-administered with IV antibiotics, Synthetic Biologics’ product candidate, SYN-004, is designed to be a preventive therapy intended to protect the gut microbiome by degrading IV antibiotics, thereby preventing the onset of C. difficile infection. Synthetic Biologics,

Read more
Share Email SHARE
Download PDF DOWNLOAD PDF
Get Code GET CODE

Tune in

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel
LISTEN LIVE
EPISODE ON DEMAND
VIEW HOST PAGE
Questions? Comments?
Call In Live!
Toll Free: 1-866-472-5792
Intl: 001-480-553-5759

Featured Guests

Guest Image

Lewis Barrett, BS, MBA

Lewis Barrett, B.S., M.B.A., Senior Vice President, Commercial Strategy, Synthetic Biologics, Inc. a biotechnology company developing novel anti-infective biologics and drugs targeting specific pathogens that cause serious infections and diseases.
Read more
Guest Image

Dr Joseph Sliman, MD, MPH

Joseph A. Sliman, MD, MPH, Senior Vice President, Clinical & Regulatory Affairs, Synthetic Biologics, Inc. a biotechnology company developing novel anti-infective biologics and drugs targeting specific pathogens that cause serious infections and diseases. Presentation Topic: "Oral Enzyme Therapy to Protect the Gut Microbiome from the Harmful Effects of IV Antibiotics for the Prevention of Clostridium difficile Infection (CDI)
Read more

Share This Episode

facebook Share On Facebook
twitter Share On Twitter
Linkedin Share On LinkedIn
Share Email Share this E-mail
https://www.voiceamerica.com/show/2441/c-diff-spores-and-more 24/10/2017 10:00 24/10/2017 11:00 C. diff. Spores and More https://www.voiceamerica.com/show/2441/c-diff-spores-and-more The majority of C. difficile cases are caused by the unintended consequences of antibiotic therapy to the gut microbiome. Intravenous (IV) antibiotics excreted to the gut often wipe out the natural balance of microflora, which can lead to recurring diarrhea and perforation of the intestinal wall, with potentially fatal outcomes. Co-administered with IV antibiotics, Synthetic Biologics’ product candidate, SYN-004, is designed to be a preventive therapy intended to protect the gut microbiome by degrading IV antibiotics, thereby preventing the onset of C. difficile infection. Synthetic Biologics, Inc.’s Lewis Barrett, BS, MBA, Senior Vice President, Commercial Strategy and Joseph A. Sliman, MD, MPH, Senior Vice President, Clinical & Regulatory Affairs will discuss the novel point-of-care preventive approach, the clinical development pathway and the potential of the Company’s lead pathogen-specific product candidate, SYN-004. VoiceAmerica | Talk Radio | Online Talk Radio studio@voiceamerica.com false DD/MM/YYYY Add to Calendar
Email Host Email the Host

Connect with VoiceAmerica

Download our mobile apps
App store Google play Blackberry store
GPlus Facebook Twitter Linkedin Social Media
presspass-banner